Charles River Laboratories International, Inc. (CRL) closed at $345.93 on November 11, 2026, declining 2.03% over the prior 24-hour period. The drop extended a modest weekly pullback, with shares also down 1.59% over the past seven days.
Despite the recent softness, the contract research organization has posted a notable 30-day gain of 14.63%, reflecting a broader recovery in the stock over the past month. The company's market capitalization stood at $16.93 billion as of the close.
The daily and weekly declines suggest some near-term selling pressure following the stock's strong monthly run. CRL's price action over the two timeframes points to a consolidation phase after the recent upward move.
Charles River Laboratories provides drug discovery and development services to the pharmaceutical and biotechnology industries. The stock's current price of $345.93 sits against the backdrop of a market capitalization that reflects its position as a significant player in the contract research sector.
